Press Releases

Full-year accounts for 2008

• Revenues: + 134% • Loramyc® is creating value • Commercial synergies in the near future • 2008 end-of-year cash reserves: €32 million BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today presented its consolidated financial results for the fiscal year ended December 31, 2008. 2008 was…read more →

BioAlliance Pharma reacquires the rights to Loramyc® in Europe

BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced the termination of the licensing agreement signed in 2007 with SpeBio (a joint venture with SpePharm). The exclusive license in European Union countries other than France covered the distribution of Loramyc®, a muco-adhesive buccal tablet for treating…read more →

BioAlliance Pharma files for European marketing authorization for ondansetron RapidFilm™ in supportive care in cancer

BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced the initiation of its European marketing application for ondansetron RapidFilm™, the fast-dissolving oral film strip formulation of ondansetron (which until now has been used in tablet form). This innovation is designed to prevent and treat nausea and…read more →

2008 consolidated turnover: +134%

Strong sales growth A pro-active partnering strategy BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced a 2008 turnover of €8.2 million, strongly increased from €3.5 million in 2007. Over the course of 2008, the company pro-actively pursued its international licensing and partnering strategy, notably via…read more →

BioAlliance Pharma presents results on a new quinoline family on HIV integrase inhibitors at the 16th Conference on Retroviruses and Opportunistic Infections (CROI)

Paris, February 6, 2009 – BioAlliance Pharma SA (Euronext Paris-BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announces the presentation of its results on a new quinoline family acting as HIV integrase inhibitors at the 16th Conference on Retroviruses and Opportunistic Infections (CROI), in Montreal, Canada (February 8 to 11, 2009). The…read more →

BioAlliance Pharma publishes its 2009 financial calendar

Paris, January 15, 2009 – BioAlliance Pharma SA (Euronext Paris – ticker code BIO) has announced its financial calendar for 2009, which notably includes the publication dates for its revenue statements and half-year & annual accounts, as well as the date of its shareholders’ Annual General Meeting: February 11, 2009 Publication of the revenue statement for Q4 2008 and of…read more →